Lipid-Lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?

Publication date: Available online 9 February 2017
Source:Clinical Therapeutics
Author(s): Leonardo Roever, Giuseppe Biondi-Zoccai, Sunil V. Rao
Cardiovascular disease is the leading cause of death in the world. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol (LDL-C) levels, is central to the development and progression of atherosclerosis. Dyslipidemia has become a primary target of intervention in strategies for the prevention of cardiovascular events. Therapeutic lifestyle changes, such as increased physical activity, weight loss, smoking cessation, and adoption of a healthier diet, are effectively reducing cardiovascular risk in primary and secondary prevention. The combination therapy lowered LDL-C levels and achieved the LDL-C target in patients with high cardiovascular risk.



http://ift.tt/2kX6yC2